Инкретинотерапия ожирения: эффективность, безопасность и приверженность

Для цитирования:

Аннотация

Ожирение остается одной из главных коморбидностей современного населения планеты, которая носит характер пандемии. К сожалению, с каждым годом констатируется стремительное увеличение распространенности ожирения как мультисистемного заболевания, затрагивающего практически все органы и системы. Доказано, что ожирение повышает риски полисоматической, канцерогенной, в том числе и гинекологической заболеваемости, а также способствует эпигенетическому ремоделированию генома потомства, индуцируя развитие эндокринно-метаболических и сердечно-сосудистых нарушений в долгосрочной перспективе. В настоящем обзоре подробно освещены вопросы эффективности, безопасности и приверженности инкретинотерапии ожирения.

Ключевые слова: ожирение, доклиническое ожирение, клиническое ожирение, критерии диагностики, агонист глюкагоноподобного пептида-1, двойной агонист глюкагоноподобного пептида-1 и глюкозозависимого инсулинотропного полипептида, семаглутид, тирзепатид.

Список литературы

1. Bowman-Busato J, Schreurs L et al. Providing a common language for obesity: the European Association for the Study of Obesity obesity taxonomy. Int J Obesity 2025;49(2):182-91.

2. Ueda Yamaguchi N, de Almeida L, Carvalho Gomes Corrêa R et al. Global Perspectives on Obesity and Being Overweight: A Bibliometric Analysis in Relation to Sustainable Development Goals. Int J Environmental Res Public Health 2025;22(2):146.

3. Phelps NH, Singleton RK, Zhou B et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 2024;403(10431):1027-50.

4. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

5. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. Available at: https://data.worldobesity.org/publications/?cat=23

6. Rubino F, Cummings DE, Eckel RH et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13(3):221-62.

7. Blüher M. An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes. Diabetes Obes Metab 2025;(27):3-19.

8. Venkatesh SS, Ferreira T, Benonisdottir S et al. Obesity and risk of female reproductive conditions: a Mendelian randomisation study. PLoS Medicine 2022;19(2):e1003679.

9. Efstratiou M, Kantilafti M, Hadjikou A, Chrysostomou S. The effect of obesity on fertility: A systematic review. Semergen 2026;52(1):102670.

10. Kweon JY, Mun H, Choi MR et al. Maternal obesity induced metabolic disorders in offspring and myeloid reprogramming by epigenetic regulation. Front Endocrinol 2024;(14):1256075.

11. Huang JS, Zhang XY, Ramakrishnan R et al. Association of Childhood Obesity Phenotypes With Cardiometabolic Outcomes in Adulthood: A Systematic Review and Meta‐Analysis. Obesity Rev 2026;27(1):1-10.

12. Vaughan OR, Goodspeed A, Sucharov CC et al. Human fetal circulating factors from pregnancies complicated by obesity upregulate genes associated with pathological hypertrophy in neonatal rat cardiomyocytes. Am J Physiol Heart Circ Physiol 2026;330(1):H124-H136.

13. Grannell A, Fallon F, Pournaras D, le Roux CW. Exploring patient beliefs and perceptions regarding obesity as a disease, obesity causation and treatment. Irish J Med Sci 2021;190(1):163-8.

14. World Health Organization. WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. 2025.

15. McGowan B, Ciudin A, Baker JL et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Med 2025;p.1-13.

16. Coskun T, Sloop KW, Loghin C et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018;(18):3-14.

17. Furihata K, Mimura H, Urva S et al. A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab 2022;24(2):239-46.

18. Chavda VP, Ajabiya J, Teli D et al. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules 2022;27(13):4315.

19. Gao L, Lee BW, Chawla M et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med 2023;29(6):1500-10.

20. Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753-86.

21. Frías JP, Davies MJ, Rosenstock J et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385(6):503-15.

22. Gastaldelli A, Cusi K, Landó LF et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10(6):393-406.

23. Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025;392(10):958-71.

24. Heise T, DeVries JH, Urva S et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 2023;46(5):998-1004.

25. Abu-Alsaud MA, Ellebedy M, Hammad N et al. Tirzepatide Versus Long-Acting Insulin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Diabetol 2025;16(3):204-13.

26. Shukla AP, Dunn JP, Gomez Valderas E et al. Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT‐5 trial. Diabetes Obes Metab 2026;28(1):452-62.

27. Hu W, Gong W, Yang F et al. Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. Int Immunopharmacol 2025;(147):113937.

28. Tian R, Liu K, Lai H et al. GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis. Int Immunopharmacol 2025;(165):115443.

29. Delvadia P, Dhote V, Mandloi AS et al. Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson’s Disease Rat Model. ACS Chem Neurosci 2025;16(5):818-25.

30. Davies MJ, van der Meer P, Verma S et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2025;13(3):196-209.

31. Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization, 2003.

32. Khan R, Socha-Dietrich K. Investing in medication adherence improves health outcomes and health system efficiency: adherence to medicines for diabetes, hypertension, and hyperlipidaemia. 2018.

33. Bhatia S, Landier W, Hageman, L et al. 2015. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a Children’s Oncology Group Study. JAMA Oncol 2015;1(3):287-95.

34. Hichborn J, Kaganoff S, Subramanian N, Yaar Z. Improving patient adherence through data-driven insights. McKinsey & Company, 2018.

35. Sharma AM, Birney S, Crotty M et al. Determinants of adherence to obesity medication: A narrative review. Obesity Rev 2025;26(5):e13885.

36. Osborne D, Abdelgadir E. Mental health outcomes in obesity interventions with GLP-1 receptor agonists: is it similar to other obesity interventions? A narrative review with systematic evidence synthesis: Behavior, Psychology and Sociology. Int J Obesity 2026;p.1-9.

37. Cengiz A, Wu CC, Lawley SD. Incretin mimetics for weight loss forgive nonadherence. Diabetes Obes Metab 2025;27(8):4109-17.

38. Оразов М.Р., Радзинский В.Е., Долгов Е.Д. Ожирение и репродукция: алгоритм действий клинициста. Клинический разбор в общей медицине. 2025;6(9):55-62. DOI: 10.47407/kr2025.6.9.00673

Orazov M.R., Radzinskiy V.E., Dolgov E.D. Obesity and reproduction: a clinician’s algorithm of actions. Clinical review for general practice. 2025;6(9):55-62. DOI: 10.47407/kr2025.6.9.00673 (in Russian).

39. McGowan B, Ciudin A, Baker JL et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nature Med 2025;p.1-4.

40. Трошина Е.А., Анциферов М.Б., Аметов А.С. и др. Персонифицированный подход к терапии ожирения на основе доказательных данных и клинических алгоритмов: семаглутид или тирзепатид. Проблемы эндокринологии. 2025;71(5):19-30. DOI: 10.14341/ probl13677

Troshina E.A., Antsiferov M.B., Ametov A.S., et al. A personalized approach to obesity therapy based on evidence and clinical algorithms: semaglutide or tirzepatide. Problems of Endocrinology. 2025; 71(5):19–30. DOI: 10.14341/probl13677 (in Russian).

Для цитирования:Оразов М.Р., Радзинский В.Е., Михалева Л.М., Балан В.Е., Долгов Е.Д. Инкретинотерапия ожирения: эффективность, безопасность и приверженность. Клинический разбор в общей медицине. 2026; 7 (2): 115–122. DOI: 10.47407/kr2026.7.2.00779

Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)

Клинический разбор в общей медицине